Used in targeted cancer therapy, particularly for hematologic malignancies such as non-Hodgkin's lymphoma. It binds specifically to TSPAN26 (CD37), a protein highly expressed on B-cell lymphocytes, enabling selective delivery of therapeutic agents or immune-mediated destruction of cancer cells. Often employed as a conjugate in antibody-drug conjugates (ADCs) to enhance cytotoxicity while minimizing damage to healthy tissues. Also investigated for use in radioimmunotherapy, where it delivers radioactive isotopes directly to tumor cells. Its high specificity improves treatment precision and supports development of personalized oncology treatments.